Skip to content

Polydatin improves mitochondrial dynamics dysrhythmia by regulating BMAL1 to prevent and treat metabolic dysfunction-associated fatty liver disease.

Jul 2026 · Journal of Ethnopharmacology · Vol 372, pp. 122195 · 2 citations · 34 references
Medicine

TL;DR

This is the first study to demonstrate that PD alleviates MAFLD by mediating BMAL1-regulated circadian rhythms of mitochondrial dynamics, positioning PD as a potential therapeutic candidate for MAFLD.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE Polygonum cuspidatum, a traditional Chinese medicine indicated for "blood stasis" and "damp-heat" disorders (e.g., arthralgia, jaundice, amenorrhea), has modern relevance as these conditions correlate with dyslipidemia, inflammation, and microcirculatory issues. Its main constituent, polydatin (PD), exhibits multiple bioactivities, yet its role in metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear.

Aim

OF THE STUDY To elucidate the mechanisms by which PD alleviates MAFLD through BMAL1-mediated mitochondrial dynamics.

Materials And Methods

FFA-induced HepG2 cells and HFD-induced MAFLD rats were used to evaluate the effects of PD on hepatic lipid accumulation, mitochondrial function, and oxidative stress immune imbalance via histological staining and biochemical assays. Additionally, molecular docking, molecular dynamics simulations, and BMAL1 knockdown experiments were conducted to identify potential upstream regulators.

Results

PD significantly suppressed lipid accumulation, reduced levels of ROS, MDA, NLRP3, TNF-α, and IL-1β, while enhancing SOD activity, thereby alleviating oxidative stress-immune imbalance. PD increased mitochondrial membrane potential (MMP), ATP content, and mtDNA copy number, reversing mitochondrial dysfunction. Notably, PD improved expression rhythms of BMAL1 and mitochondrial dynamics-related genes (DRP1, OPA1, MFN1, MFN2, FIS1), normalizing their amplitude and phase. Concurrently, PD activated the mitochondrial autophagy pathway by upregulating PINK1 and PARKIN expression, thereby facilitating timely clearance of impaired mitochondria. Most importantly, all the aforementioned therapeutic benefits of PD were abolished upon BMAL1 knockdown, establishing BMAL1 as an essential target for PD's action.

Conclusion

This is the first study to demonstrate that PD alleviates MAFLD by mediating BMAL1-regulated circadian rhythms of mitochondrial dynamics, positioning PD as a potential therapeutic candidate for MAFLD.

View source

Similar papers

Open access Aug 2026

Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis

Background Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease with limited pharmacological treatment options. Wogonoside (WOG), a flavonoid isolated from Scutellaria baicalensis, exhibits anti-inflammatory, antioxidant, and lipid-low...

Daoping Wang, Yu Mou, Xue-Mei Wu et al. · 0 citations
Open access Sep 2026

Yinqi Tiaozhi Decoction ameliorates hepatic steatosis in metabolic dysfunction-associated fatty liver disease by regulating the miR-122-5p/FOXO3 axis to modulate lipid metabolism and oxidative stress

YQTZD mitigates hepatic steatosis, oxidative damage, and inflammation in MAFLD, mechanistically linked to miR-122-5p downregulation-mediated FOXO3 upregulation and provides a mechanistic foundation for its future integration into clinical management of MAFLD.

Li-Ping Zhou, Yan-Feng Huang, F. Tian et al. · 0 citations
Open access Sep 2026

Regulation of hepatic mitochondrial function by AIBP mitigates MASLD development.

Findings identify AIBP as a critical regulator of hepatic mitochondrial function and lipid metabolism and support AIBP as a potential therapeutic target for preventing the progression of MASLD to MASH.

Soo-Ho Choi, Subham Sharma, Seunghwan Choi et al. · 0 citations
Aug 2026

Erchen Decoction Alleviates MAFLD by Regulating MFN2-mediated Endoplasmic Reticulum Stress.

EC exerts significant protective effects against MAFLD by upregulating the MFN2/ERMIT2 axis and suppressing the PERK, eIF2α, and ATF4 ERS pathway, suggesting a restorative effect on calcium handling, maintains ER homeostasis, and reduces hepatocyte injury, highlighting EC as a promising therapeutic candidate for MAFLD.

Qing-Xuan He, Meng-Zhen Wang, Xu Wang et al. · 0 citations
Open access Aug 2026

Polydatin in combination with hawthorn flavonoids alleviates atherosclerosis by inhibiting mitochondrial division through the YTHDF2-DRP1 axis.

PH exerts a protective effect on HUVECs and prevents AS by regulating the YTHDF2/DRP1 axis to restore mitochondrial homeostasis, thereby providing a novel therapeutic approach for AS.

Yu-Juan Li, Xiao-Nan Zhang, Sheng-Jie Yang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.